Our Annual Meeting identifies actionable opportunities to drive progress in cancer research and care. Over the years, our Annual Meeting expert working groups and white papers have provided the foundation for launching several collaborative research initiatives and informed development of regulatory policy and legislation including:

• Our 2011 and 2012 Annual Meeting white papers proposed criteria that guided the implementation of the Breakthrough Therapy Designation.
• Our 2016 Annual Meeting white paper on eligibility criteria launched our partnership with ASCO on broadening eligibility criteria, culminating in a series of FDA guidance documents on broadening eligibility criteria in cancer clinical trials.
• Our 2018 Annual Meeting white paper, “Exploring the Use of ctDNA as a Monitoring Tool for Drug Development,” led to the launch of our ongoing ctMoniTR research partnership.
• Our 2018 Annual Meeting white paper on Real-time Oncology Review (RTOR) and Assessment Aid provided considerations that supported full implementation of the pilot programs.
• Our 2021 and 2022 Annual Meeting white papers on optimizing dosing and leveraging patient-reported outcomes (PROs) in early phase dosing studies, informed FDA guidance on “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.”

Explore our Annual Meeting white papers, topics, and full video sessions by clicking through the tabs and flip cards below.